Regencell Bioscience Holdings Ltd (RGC)
5.48
+0.26
(+4.98%)
USD |
NASDAQ |
Apr 19, 16:00
5.48
0.00 (0.00%)
After-Hours: 17:01
Regencell Bioscience Holdings Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 56.32M |
| April 17, 2024 | 50.04M |
| April 16, 2024 | 36.67M |
| April 15, 2024 | 36.67M |
| April 12, 2024 | 37.97M |
| April 11, 2024 | 37.84M |
| April 10, 2024 | 36.15M |
| April 09, 2024 | 37.71M |
| April 08, 2024 | 39.14M |
| April 05, 2024 | 39.14M |
| April 04, 2024 | 36.80M |
| April 03, 2024 | 38.69M |
| April 02, 2024 | 40.45M |
| April 01, 2024 | 39.14M |
| March 28, 2024 | 46.95M |
| March 27, 2024 | 33.55M |
| March 26, 2024 | 33.29M |
| March 25, 2024 | 36.54M |
| March 22, 2024 | 33.94M |
| March 21, 2024 | 38.36M |
| March 20, 2024 | 40.32M |
| March 19, 2024 | 41.10M |
| March 18, 2024 | 46.95M |
| March 15, 2024 | 48.58M |
| March 14, 2024 | 52.03M |
| Date | Value |
|---|---|
| March 13, 2024 | 61.40M |
| March 12, 2024 | 46.95M |
| March 11, 2024 | 46.95M |
| March 08, 2024 | 46.95M |
| March 07, 2024 | 53.20M |
| March 06, 2024 | 63.48M |
| March 05, 2024 | 63.48M |
| March 04, 2024 | 66.47M |
| March 01, 2024 | 73.50M |
| February 29, 2024 | 76.23M |
| February 28, 2024 | 80.27M |
| February 27, 2024 | 83.00M |
| February 26, 2024 | 81.44M |
| February 23, 2024 | 86.90M |
| February 22, 2024 | 86.90M |
| February 21, 2024 | 89.76M |
| February 20, 2024 | 89.76M |
| February 16, 2024 | 92.50M |
| February 15, 2024 | 85.99M |
| February 14, 2024 | 85.47M |
| February 13, 2024 | 85.47M |
| February 12, 2024 | 85.99M |
| February 09, 2024 | 85.03M |
| February 08, 2024 | 90.03M |
| February 07, 2024 | 90.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
33.29M
Minimum
Mar 26 2024
595.80M
Maximum
Jun 15 2022
289.62M
Average
319.49M
Median
Enterprise Value Benchmarks
| Global Pharmatech Inc | -- |
| NovaBay Pharmaceuticals Inc | 2.485M |
| Palatin Technologies Inc | 21.01M |
| iBio Inc | 16.03M |
| Theriva Biologics Inc | -12.54M |